Protective role of salidroside against aging in a mouse model induced by D-galactose.
OBJECTIVE
To investigate the protective effects of putative AGEs (advanced glycation endproducts) inhibitor salidroside against aging in an accelerated mouse aging model induced by D-galactose.


METHODS
A group of 5-month-old C57BL/6J mice were treated daily with D-galactose, D-galactose combined with salidroside, salidroside alone, and control buffer for 8 weeks. At the end of the treatment, serum AGEs levels, neurological activities, expression of glial fibrillary acidic protein (GFAP) and neurotrophin-3 (NT-3) in the cerebral cortex, as well as lymphocyte proliferation and IL-2 production were determined.


RESULTS
D-galactose induced mouse aging model was developed as described before. As expected, salidroside blocked D-galactose induced increase of serum AGEs levels. It also reversed D-galactose induced aging effects in neural and immune system, as evidenced by improving motor activity, increasing memory latency time, and enhancing lymphocyte mitogenesis and interleukin-2 (IL-2) production. Furthermore, elevated expression of GFAP and NT-3 in the aged model mice was also reduced upon salidroside treatment.


CONCLUSIONS
Salidroside inhibits AGEs formation in vivo, which at least partially contributes to its anti-aging effect in D-galactose induced aging model.
Mao
Gen-Xiang
GX
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Deng
Hong-Bin
HB
Yuan
Long-Guo
LG
Li
Dian-Dong
DD
Li
Yi-Yang Yvonne
YY
Wang
Zhen
Z
D019588:Aging, Premature / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D005690:Galactose; D005904:Glial Fibrillary Acidic Protein; D005960:Glucosides / Q000494:pharmacology / Q000627:therapeutic use*; D017127:Glycation End Products, Advanced / Q000097:blood; D007376:Interleukin-2 / Q000378:metabolism; D008568:Memory / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects; D009414:Nerve Growth Factors / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000378:metabolism; D010636:Phenols / Q000494:pharmacology / Q000627:therapeutic use*; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects
D004365:Drugs, Chinese Herbal; D005904:Glial Fibrillary Acidic Protein; D005960:Glucosides; D017127:Glycation End Products, Advanced; D007376:Interleukin-2; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D010636:Phenols; C528900:glial fibrillary astrocytic protein, mouse; C518911:neurotropin 3, mouse; C009172:rhodioloside; D005690:Galactose